Peter Krein, Ph.D.

Peter Krein, Ph.D., has over 15 years of experience at diagnostic and pharmaceutical companies and has a wealth of experience developing and commercializing companion diagnostics in oncology.

Prior to Boundless Bio, Dr. Krein served as Executive Director, Diagnostic Development and Medical Affairs at Loxo Oncology at Lilly, where he led global diagnostic strategies for precision oncology therapeutics.  Prior to joining Loxo Oncology, Dr. Krein spent two years as Managing Director at Diaceutics Group, where he advised several global pharmaceutical companies on effective integration of diagnostics into drug development and commercialization strategies. Prior to Diaceutics, Dr. Krein held leadership roles developing in vitro diagnostics and companion diagnostics at Qiagen, GenMark Diagnostics, Luminex Corporation, and Roche Tissue Diagnostics. 

Dr. Krein holds a Ph.D. in Molecular Immunology & Oncology from the University of Calgary and completed a postdoctoral fellowship in functional genomics at the University of Arizona.